| Year |
Citation |
Score |
| 2023 |
Overholser J, Guo L, Kaumaya PTP. Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction. Journal of Visualized Experiments : Jove. PMID 37486131 DOI: 10.3791/65467 |
0.415 |
|
| 2022 |
Guo L, Overholser J, Darby H, Ede NJ, Kaumaya PTP. A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx). Oncoimmunology. 11: 2127691. PMID 36211807 DOI: 10.1080/2162402X.2022.2127691 |
0.375 |
|
| 2022 |
Guo L, Overholser J, Good AJ, Ede NJ, Kaumaya PTP. Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys). Frontiers in Oncology. 12: 826566. PMID 35646678 DOI: 10.3389/fonc.2022.826566 |
0.314 |
|
| 2021 |
Guo L, Kaumaya PTP. First prototype checkpoint inhibitor B-cell epitope vaccine (PD1-Vaxx) en route to human Phase 1 clinical trial in Australia and USA: exploiting future novel synergistic vaccine combinations. British Journal of Cancer. PMID 33772155 DOI: 10.1038/s41416-021-01342-9 |
0.364 |
|
| 2020 |
Kaumaya PTP, Guo L, Overholser J, Penichet ML, Bekaii-Saab T. Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model. Oncoimmunology. 9: 1818437. PMID 33117602 DOI: 10.1080/2162402X.2020.1818437 |
0.371 |
|
| 2020 |
Kaumaya PT. B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. Future Oncology (London, England). PMID 32564612 DOI: 10.2217/fon-2020-0224 |
0.63 |
|
| 2020 |
Kaumaya P, Bekaii-Saab T, Phan T, Marino MT, Ede N, Good A. Abstract CT128: IMU-201-101 - an open-label, multi-center, dose escalation/expansion, phase 1 study of IMU-201 (PD1-Vaxx), a B-cell immunotherapy, in adults with non-small cell lung cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct128 |
0.388 |
|
| 2019 |
Bekaii-Saab T, Wesolowski R, Ahn DH, Wu C, Mortazavi A, Lustberg MB, Ramaswamy B, Fowler J, Wei L, Overholser J, Kaumaya PTP. Phase 1 Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines emulsified in Montanide ISA 720VG and nor-MDP Adjuvant in Advanced Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30804020 DOI: 10.1158/1078-0432.CCR-18-3997 |
0.55 |
|
| 2019 |
Bekaii-Saab T, Wei L, Wesolowski R, Ahn D, Wu C, Lustberg M, Mortazavi A, Ramaswamy B, Overholser J, Kaumaya P. Abstract CT017: A Phase Ib of a combination of two chimeric (Trastuzumab-like and Pertuzumab-like) HER-2 B cell peptide vaccine emulsified in ISA 720 and nor-MDP adjuvant in patients with advanced solid tumors Clinical Trials. DOI: 10.1158/1538-7445.Sabcs18-Ct017 |
0.568 |
|
| 2019 |
Bekaii-Saab T, Overholser J, Yang Y, Penichet M, Kaumaya P. Abstract 1453: Development of a novel PD-1 vaccine and in combination with two Chimeric HER-2 peptide vaccine provides synergistic inhibition of tumor growth in a syngeneic Balb/c model challenged with CT26/HER-2 carcinoma cell line Cancer Research. 79: 1453-1453. DOI: 10.1158/1538-7445.Am2019-1453 |
0.586 |
|
| 2016 |
Barth RF, Wu G, Meisen WH, Nakkula RJ, Yang W, Huo T, Kellough DA, Kaumaya P, Turro C, Agius LM, Kaur B. Design, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumors. Oncotargets and Therapy. 9: 2769-2781. PMID 27274273 DOI: 10.2147/Ott.S99242 |
0.347 |
|
| 2015 |
Overholser J, Ambegaokar KH, Eze SM, Sanabria-Figueroa E, Nahta R, Bekaii-Saab T, Kaumaya PT. Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). Vaccines. 3: 519-43. PMID 26350593 DOI: 10.3390/Vaccines3030519 |
0.443 |
|
| 2015 |
Kaumaya PT. A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy. Human Vaccines & Immunotherapeutics. 11: 1368-86. PMID 25874884 DOI: 10.1080/21645515.2015.1026495 |
0.468 |
|
| 2014 |
Miller MJ, Foy KC, Overholser JP, Nahta R, Kaumaya PT. HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells. Oncoimmunology. 3: e956012. PMID 25941588 DOI: 10.4161/21624011.2014.956012 |
0.483 |
|
| 2014 |
Foy KC, Miller MJ, Overholser J, Donnelly SM, Nahta R, Kaumaya PT. IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides. Oncoimmunology. 3: e956005. PMID 25941587 DOI: 10.4161/21624011.2014.956005 |
0.441 |
|
| 2014 |
De G, Ko J, Lin P, Kaumaya P, Li H, Ma J. Amphipathic Tail-Anchoring Peptide is a Promising Therapeutic Agent for Cancer Treatment Biophysical Journal. 106: 1-6. DOI: 10.1016/J.Bpj.2013.11.1049 |
0.517 |
|
| 2013 |
Kaumaya PT. Bridging oncology and immunology: expanding horizons with innovative peptide vaccines and peptidomimetics. Immunotherapy. 5: 1159-63. PMID 24188668 DOI: 10.2217/imt.13.128 |
0.559 |
|
| 2013 |
Foy KC, Wygle RM, Miller MJ, Overholser JP, Bekaii-Saab T, Kaumaya PT. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo. Journal of Immunology (Baltimore, Md. : 1950). 191: 217-27. PMID 23698748 DOI: 10.4049/jimmunol.1300231 |
0.585 |
|
| 2013 |
Miller MJ, Foy KC, Kaumaya PT. Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics. Discovery Medicine. 15: 166-76. PMID 23545045 |
0.343 |
|
| 2013 |
Foy KC, Miller MJ, Moldovan N, Carson WE, Kaumaya PP. Correction to: Foy KC, Miller MJ, Moldovan N, Carson III WE, Kaumaya PTP. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. OncoImmunology 2012; 1:1048-1060. Oncoimmunology. 2: e23914. PMID 23479552 DOI: 10.4161/Onci.23914 |
0.439 |
|
| 2012 |
Foy KC, Miller MJ, Moldovan N, Carson WE, Kaumaya PT. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. Oncoimmunology. 1: 1048-1060. PMID 23170253 DOI: 10.4161/onci.20708 |
0.508 |
|
| 2012 |
Kaumaya PT, Foy KC. Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncology (London, England). 8: 961-87. PMID 22894670 DOI: 10.2217/fon.12.95 |
0.498 |
|
| 2011 |
Kaumaya PT. Could precision-engineered peptide epitopes/vaccines be the key to a cancer cure? Future Oncology (London, England). 7: 807-10. PMID 21732751 DOI: 10.2217/fon.11.60 |
0.523 |
|
| 2011 |
Foy KC, Liu Z, Phillips G, Miller M, Kaumaya PT. Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo. The Journal of Biological Chemistry. 286: 13626-37. PMID 21325276 DOI: 10.1074/jbc.M110.216820 |
0.341 |
|
| 2011 |
Peterson JM, Kline W, Canan BD, Ricca DJ, Kaspar B, Delfín DA, DiRienzo K, Clemens PR, Robbins PD, Baldwin AS, Flood P, Kaumaya P, Freitas M, Kornegay JN, Mendell JR, et al. Peptide-based inhibition of NF-κB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy. Molecular Medicine (Cambridge, Mass.). 17: 508-15. PMID 21267511 DOI: 10.2119/Molmed.2010.00263 |
0.441 |
|
| 2010 |
Wang B, Kaumaya PT, Cohn DE. Immunization with synthetic VEGF peptides in ovarian cancer. Gynecologic Oncology. 119: 564-70. PMID 20822802 DOI: 10.1016/j.ygyno.2010.07.037 |
0.384 |
|
| 2010 |
Chen J, Chen CL, Rawale S, Chen CA, Zweier JL, Kaumaya PT, Chen YR. Peptide-based antibodies against glutathione-binding domains suppress superoxide production mediated by mitochondrial complex I. The Journal of Biological Chemistry. 285: 3168-80. PMID 19940158 DOI: 10.1074/Jbc.M109.056846 |
0.346 |
|
| 2009 |
Kaumaya PT, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, Lamb T, Mani A, Kane Y, Balint CR, Chalupa D, Otterson GA, Shapiro CL, Fowler JM, Grever MR, et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5270-7. PMID 19752336 DOI: 10.1200/JCO.2009.22.3883 |
0.395 |
|
| 2007 |
Allen SD, Garrett JT, Rawale SV, Jones AL, Phillips G, Forni G, Morris JC, Oshima RG, Kaumaya PT. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. Journal of Immunology (Baltimore, Md. : 1950). 179: 472-82. PMID 17579068 DOI: 10.4049/Jimmunol.179.1.472 |
0.45 |
|
| 2007 |
Garrett JT, Rawale S, Allen SD, Phillips G, Forni G, Morris JC, Kaumaya PT. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu. Journal of Immunology (Baltimore, Md. : 1950). 178: 7120-31. PMID 17513761 DOI: 10.4049/Jimmunol.178.11.7120 |
0.614 |
|
| 2006 |
Lynch MP, Kaumaya PT. Advances in HTLV-1 peptide vaccines and therapeutics. Current Protein & Peptide Science. 7: 137-45. PMID 16611139 |
0.62 |
|
| 2005 |
Allen SD, Rawale SV, Whitacre CC, Kaumaya PT. Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade. The Journal of Peptide Research : Official Journal of the American Peptide Society. 65: 591-604. PMID 15885118 DOI: 10.1111/j.1399-3011.2005.00256.x |
0.436 |
|
| 2005 |
Kimura Y, Gushima T, Rawale S, Kaumaya P, Walker CM. Escape mutations alter proteasome processing of major histocompatibility complex class I-restricted epitopes in persistent hepatitis C virus infection. Journal of Virology. 79: 4870-6. PMID 15795272 DOI: 10.1128/Jvi.79.8.4870-4876.2005 |
0.347 |
|
| 2005 |
Dakappagari NK, Sundaram R, Rawale S, Liner A, Galloway DR, Kaumaya PT. Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic T-cell responses in HLA-A*201 mice. The Journal of Peptide Research : Official Journal of the American Peptide Society. 65: 189-99. PMID 15705163 DOI: 10.1111/J.1399-3011.2005.00212.X |
0.785 |
|
| 2005 |
Dakappagari NK, Lute KD, Rawale S, Steele JT, Allen SD, Phillips G, Reilly RT, Kaumaya PT. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities. The Journal of Biological Chemistry. 280: 54-63. PMID 15507452 DOI: 10.1074/Jbc.M411020200 |
0.784 |
|
| 2004 |
Sundaram R, Lynch MP, Rawale S, Dakappagari N, Young D, Walker CM, Lemonnier F, Jacobson S, Kaumaya PT. Protective efficacy of multiepitope human leukocyte antigen-A*0201 restricted cytotoxic T-lymphocyte peptide construct against challenge with human T-cell lymphotropic virus type 1 Tax recombinant vaccinia virus. Journal of Acquired Immune Deficiency Syndromes (1999). 37: 1329-39. PMID 15483462 DOI: 10.1097/00126334-200411010-00001 |
0.762 |
|
| 2004 |
Sundaram R, Lynch MP, Rawale SV, Sun Y, Kazanji M, Kaumaya PT. De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies. The Journal of Biological Chemistry. 279: 24141-51. PMID 15060075 DOI: 10.1074/Jbc.M313210200 |
0.733 |
|
| 2004 |
Sundaram R, Beebe M, Kaumaya PT. Structural and immunogenicity analysis of chimeric B-cell epitope constructs derived from the gp46 and gp21 subunits of the envelope glycoproteins of HTLV-1. The Journal of Peptide Research : Official Journal of the American Peptide Society. 63: 132-40. PMID 15009534 |
0.665 |
|
| 2003 |
Sundaram R, Sun Y, Walker CM, Lemonnier FA, Jacobson S, Kaumaya PT. A novel multivalent human CTL peptide construct elicits robust cellular immune responses in HLA-A*0201 transgenic mice: implications for HTLV-1 vaccine design. Vaccine. 21: 2767-81. PMID 12798617 DOI: 10.1016/S0264-410X(03)00179-8 |
0.752 |
|
| 2003 |
Dakappagari NK, Pyles J, Parihar R, Carson WE, Young DC, Kaumaya PT. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. Journal of Immunology (Baltimore, Md. : 1950). 170: 4242-53. PMID 12682258 DOI: 10.4049/Jimmunol.170.8.4242 |
0.775 |
|
| 2002 |
Sundaram R, Dakappagari NK, Kaumaya PT. Synthetic peptides as cancer vaccines. Biopolymers. 66: 200-16. PMID 12385038 DOI: 10.1002/Bip.10258 |
0.771 |
|
| 2002 |
Srinivasan M, Gienapp IE, Stuckman SS, Rogers CJ, Jewell SD, Kaumaya PT, Whitacre CC. Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28. Journal of Immunology (Baltimore, Md. : 1950). 169: 2180-8. PMID 12165548 |
0.526 |
|
| 2001 |
Frangione-Beebe M, Rose RT, Kaumaya PTP, Schwendeman SP. Microencapsulation of a synthetic peptide epitope for HTLV-1 in biodegradable poly(D,L-lactide-co-glycolide) microspheres using a novel encapsulation technique Journal of Microencapsulation. 18: 663-677. PMID 11508771 DOI: 10.1080/02652040110055216 |
0.532 |
|
| 2001 |
Srinivasan M, Wardrop RM, Gienapp IE, Stuckman SS, Whitacre CC, Kaumaya PT. A retro-inverso peptide mimic of CD28 encompassing the MYPPPY motif adopts a polyproline type II helix and inhibits encephalitogenic T cells in vitro. Journal of Immunology (Baltimore, Md. : 1950). 167: 578-85. PMID 11418697 DOI: 10.4049/Jimmunol.167.1.578 |
0.613 |
|
| 2001 |
Frangione-Beebe M, Albrecht B, Dakappagari N, Travis Rose R, Brooks CL, Schwendeman SP, Lairmore MD, Kaumaya PT. Erratum to “Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide” [Vaccine 19 (2001) 1068–1081] Vaccine. 19: 4087. DOI: 10.1016/S0264-410X(01)00201-8 |
0.464 |
|
| 2000 |
Frangione-Beebe M, Albrecht B, Dakappagari N, Rose RT, Brooks CL, Schwendeman SP, Lairmore MD, Kaumaya PT. Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide. Vaccine. 19: 1068-81. PMID 11137241 DOI: 10.1016/S0264-410X(00)00340-6 |
0.645 |
|
| 2000 |
Dakappagari NK, Douglas DB, Triozzi PL, Stevens VC, Kaumaya PT. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Research. 60: 3782-9. PMID 10919651 |
0.776 |
|
| 1997 |
Bakaletz LO, Leake ER, Billy JM, Kaumaya PT. Relative immunogenicity and efficacy of two synthetic chimeric peptides of fimbrin as vaccinogens against nasopharyngeal colonization by nontypeable Haemophilus influenzae in the chinchilla. Vaccine. 15: 955-61. PMID 9261941 DOI: 10.1016/S0264-410X(96)00298-8 |
0.442 |
|
| 1995 |
Conrad SF, Eiden JS, Chung EAL, DiGeorge AM, Powell JE, Stevens VC, Kaumaya PTP. Folding and immunogenicity of zinc-finger peptide constructs corresponding to loop regions of the protein antigens LDH-C4 and ?-hCG Letters in Peptide Science. 1: 179-196. DOI: 10.1007/BF00117954 |
0.422 |
|
| 1993 |
Srinivasan M, Domanico SZ, Kaumaya PT, Pierce SK. Peptides of 23 residues or greater are required to stimulate a high affinity class II-restricted T cell response. European Journal of Immunology. 23: 1011-6. PMID 8386663 DOI: 10.1002/Eji.1830230504 |
0.661 |
|
| 1993 |
Kaumaya PT, Kobs-Conrad S, Seo YH, Lee H, VanBuskirk AM, Feng N, Sheridan JF, Stevens V. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity. Journal of Molecular Recognition : Jmr. 6: 81-94. PMID 7508238 DOI: 10.1002/Jmr.300060206 |
0.591 |
|
| 1990 |
Smolenski LA, Kaumaya P, Atassi MZ, Pierce SK. Characteristics of peptides which compete for presented antigen-binding sites on antigen-presenting cells European Journal of Immunology. 20: 953-960. PMID 2162778 |
0.519 |
|
| 1988 |
Pierce SK, Morris JF, Grusby MJ, Kaumaya P, van Buskirk A, Srinivasan M, Crump B, Smolenski LA. Antigen-presenting function of B lymphocytes. Immunological Reviews. 106: 149-80. PMID 3075588 DOI: 10.1111/J.1600-065X.1988.Tb00778.X |
0.664 |
|
| 1988 |
Casten LA, Kaumaya P, Pierce SK. Enhanced T cell responses to antigenic peptides targeted to B cell surface Ig, Ia, OR class I molecules Journal of Experimental Medicine. 168: 171-180. PMID 2840479 DOI: 10.1084/Jem.168.1.171 |
0.53 |
|
| Show low-probability matches. |